

Leishmaniasis

IRAN (ISLAMIC REPUBLIC OF)



Country General Information (WHO 2013)


Country Gen	ieral information (WHO, 2	2013)							
Total population:	77,447,000	Age group <15/>14 yea	rs, %:	24% / 76%					
Gender (%, F/M):	49.7% / 50.3%	Life expectancy at birth	in years (F/M):	76 / 72					
GDP (PPP int \$):	15 600	Number of 3rd sub-nation	onal administrative level	999, District					
Income status:	Upper middle	divisions, name:		555, District					
Epidemiolog	V								
	, ,	VL ACL		ZCL	MCL				
Endemicity status:		Endemic	Endemic	Endemic	Non endemic				
Number of new cas	es (incidence):	52	2224	18722	N/A				
Number of relapse	cases:	2	67	135	N/A				
Total number of cases:		54	2291	18857	N/A				
Imported cases (n, %):		28 52%	363 16%	4761 25%	No data				
Gender distribution (% F):		39%	50%	41%	N/A				
Age group distribution (%, <5/5-14/>14):		(80 / 11 / 9)	(8 / 23 / 69)	(1 / 20 / 66)	N/A				
Incidence rate (cases/10 000 population in endemic		0.03	2.31	7.58	N/A				
areas ^a):									
Number of endemic 3rd sub-national administrative level divisions (n):		30 160		842	N/A				
Population at risk ¹ (%, n/total):	27% (20592663/ 75156975)	13% (9644311 / 75156975)	32% (24706766 / 75156975)	N/A				
Was there any outb	Was there any outbreak?		No	Yes	N/A				
Number of new ² for	i:	No data	No data	No data	N/A				
N/A = not applicable VL = visceral leishmaniasis ACL = anthroponotic cutaneous leishmaniasis ZCL = zoonotic cutaneous leishmaniasis MCL = mucocutaneous leishmaniasis									

Monthly distribution of new cases January-December


Number of new CL cases reported by month in

201	4 JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	ОСТ	NOV	DEC
VL	3	9	6	3	3	3	5	10	1	4	3	4
ACL	204	205	150	216	219	243	194	162	177	135	154	165
ZCL	2718	2183	1402	395	403	280	337	676	1488	2491	3065	3284


Number of new VL cases



Number of new (primary) VL cases reported by month in 2013 and 2014



Indicence rate/10 000 population and number of new CL (left) and new (primary) VL (right) cases from 1998 to 2014



^a The denominator is the population at risk as defined in Shirzadi et al, 2015.

¹ Defined as "Number of people living in 3rd sub-national administrative level endemic areas", as for the Shirzadi et al, 2015


² For this reporting period, an area at the 3rd sub-national administrative level reporting cases for the first time ever

³ Incidence rate at the national level



Distribution of new CL (left) and new (primary) VL (right) cases

Incidence of CL in Islamic republic of Iran in 2014 at province level, per 10 000 population



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. Map production: WHO/HTM/NTD/IDM

Control and surveillance

Year Leishmaniasis National Control Programme (LNCP) was established:	2007	Year latest national guidelines were published:	2007
Type of surveillance:	Integrated	Is leishmaniasis notifiable (mandatory reporting)?	Yes
Is there a vector control programme?	Yes	Is there a reservoir host control programme?	Yes
Type of insecticide used for IRS:	Deltamethrin	Number of leishmaniasis health facilities:	1002

Country
Country
County
County

Diagnosis

	VL ACL		ACL	ZCL	MCL		
Number of people screened actively for:	0 0		0	0	N/A		
Number of people screened passively for:	54	4	2291		18857	N/A	
VL cases diagnosed by RDT* (%, RDT+/total VL cases):	40%	(21 / 54)	N/A		N/A	N/A	
Proportion of positive RDT* (%, RDT+/total RDT):	100%	(21 / 21)	N/A		N/A	N/A	
Cases diagnosed by direct exam (parasitology) (%, # slides +/total cases):	22%	(12 / 54)	98%	(2245 / 2291)	74% (14012 / 18857)	N/A	
Proportion of positive slides (%, slides +/total slides):	80%	(12 / 15)	100%	(2245 / 2250)	99% (14012 / 14219)	N/A	
Cases diagnosed clinically (%, nb clinical cases/ total cases):	100%	(54 / 54)	2%	(41 / 2291)	25% (4638 / 18857)	N/A	
Percentage of cases with HIV-VL coinfection:	n HIV-VL coinfection: 0% (0 / 54)			N/A	N/A	N/A	
* These indicators apply only for primary VL cases VL = visceral leishmaniasis ACL = anthroponotic cutaneous leishmaniasis ZCL = zoonotic cutaneous leishmaniasis							

N/A = not applicable RDT = rapid diagnostic test HIV = human i

HIV = human immunodeficiency virus

Yes

ZCL = zoonotic cutaneous leishmaniasis MCL = mucocutaneous leishmaniasis

Treatment and medicines

Is treatment provided free of charge in the public sector? Antileishmanial medicines included in the national List of Essentials Medicines:

Antiersminania medicines included in the national List of Essentials Medicines. Meglumine antimoniate , miltefosine

TREATMENT OUTCOME			VL			
Proportion of relapse cases: ⁴		4%	(2 / 54)			
Initial cure rate:		80%	(43 / 54)			
Failure ⁵ rate:		0%	(0 / 54)			
Case-fatality rate:		0%	(0 / 54)			
⁴ A relapse case in this country is defined as:	For CL: Case that after having received complete local or systemic treatment is considered cured and then the disease reappears in the same area. For VL: Case with symptoms reappearing 6 months after completing treatment.					
⁵ A failure case in this country is defined as:	failure case in this country is defined as: Case with no clinical cure or reappearance of symptoms within 2 weeks after completing treatment.					